News · 26 weeks52-14%
2026-04-192026-10-11
Mix2990d
- SEC Filings14(48%)
- Insider6(21%)
- Other5(17%)
- Earnings2(7%)
- Leadership1(3%)
- Analyst1(3%)
Latest news
25 items- SECSEC Form 8-K filed by TELA Bio Inc.8-K - TELA Bio, Inc. (0001561921) (Filer)
- SECSEC Form 8-K filed by TELA Bio Inc.8-K - TELA Bio, Inc. (0001561921) (Filer)
- SECTELA Bio Inc. filed SEC Form 8-K: Other Events8-K - TELA Bio, Inc. (0001561921) (Filer)
- PRTELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue ReinforcementMALVERN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Company's Liora Monofilament Scaffold ("Liora") product. Liora is a fully resorbable surgical mesh device for soft tissue reinforcement that will enable TELA Bio to expand its footprint in the soft tissue reconstruction market and is the first implant to be fully developed in the Company’s ISO 8 certified cleanroom in Malvern, PA. "FDA 510(k) clearance is a significant milestone for TELA
- SECTELA Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - TELA Bio, Inc. (0001561921) (Filer)
- ANALYSTCraig Hallum initiated coverage on TELA Bio with a new price targetCraig Hallum initiated coverage of TELA Bio with a rating of Buy and set a new price target of $2.00
- INSIDERDirector Capper Joseph H bought $88,795 worth of shares (75,000 units at $1.18), increasing direct ownership by 72% to 179,827 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- SECTELA Bio Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - TELA Bio, Inc. (0001561921) (Filer)
- INSIDERDirector Capper Joseph H bought $78,442 worth of shares (75,000 units at $1.05), increasing direct ownership by 251% to 104,827 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- SECSEC Form DEF 14A filed by TELA Bio Inc.DEF 14A - TELA Bio, Inc. (0001561921) (Filer)
- SECSEC Form PRE 14A filed by TELA Bio Inc.PRE 14A - TELA Bio, Inc. (0001561921) (Filer)
- SECTELA Bio Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TELA Bio, Inc. (0001561921) (Filer)
- PRTELA Bio Announces COO / CFO Transition and Strategic Cost Reduction InitiativeMALVERN, Pa., Aug. 31, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that Roberto Cuca, Chief Operating Officer and Chief Financial Officer, will step down from the role effective today. "On behalf of the Board and management team, I would like to thank Roberto for his many contributions to TELA Bio over the past five years," said Heather Getz, Chief Executive Officer of TELA Bio. "Roberto has been instrumental in helping us scale operations in support of the Company’s long-term growth aspirations. We are deeply grateful for his commi
- INSIDERChief Executive Officer Getz Heather C bought $8,311 worth of shares (12,500 units at $0.66), increasing direct ownership by 2% to 532,500 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERChief Executive Officer Getz Heather C bought $10,467 worth of shares (15,000 units at $0.70), increasing direct ownership by 3% to 520,000 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by TELA Bio Inc.SCHEDULE 13G/A - TELA Bio, Inc. (0001561921) (Subject)
- SECAmendment: TELA Bio Inc. filed SEC Form 8-K: Leadership Update8-K/A - TELA Bio, Inc. (0001561921) (Filer)
- SECSEC Form S-8 filed by TELA Bio Inc.S-8 - TELA Bio, Inc. (0001561921) (Filer)
- SECSEC Form 10-Q filed by TELA Bio Inc.10-Q - TELA Bio, Inc. (0001561921) (Filer)
- SECTELA Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TELA Bio, Inc. (0001561921) (Filer)
- PRTELA Bio Reports Second Quarter 2026 Financial ResultsMALVERN, Pa., Aug. 10, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended June 30, 2026. Recent Highlights Announced appointment of Heather Getz as Chief Executive Officer and Director, effective August 4, 2026;Delivered international revenue growth of 26% over the prior year period, with continued momentum in several European markets;Achieved additional market share gain with OviTex unit volume growth of 12% over the prior year period;Grew LiquiFix revenue by 39% over the prior-year period; andDelivered $19.3
- INSIDERChief Executive Officer Getz Heather C was granted 500,000 shares, increasing direct ownership by 10,000% to 505,000 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERNew insider Getz Heather C claimed ownership of 5,000 shares (SEC Form 3)3 - TELA Bio, Inc. (0001561921) (Issuer)
- PRTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)MALVERN, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Board of Directors of TELA Bio approved inducement grants of stock options to purchase an aggregate of 2,370,000 shares of its common stock and restricted stock units covering 500,000 shares of its common stock to the Company’s newly-hired Chief Executive Officer, Heather Getz, with a grant date of August 3, 2026 (the "Getz Grant Date"). The stock options consist of (i) stock options to purchase 1,365,000 shares of common stock (the "Standard Options") and (ii)
- SECSEC Form S-8 filed by TELA Bio Inc.S-8 - TELA Bio, Inc. (0001561921) (Filer)
TELA FAQ
7 questionsWhat does TELA Bio Inc. do?
TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be...Where does TELA stock trade?
TELA Bio Inc. (TELA) is listed on NASDAQ.What sector and industry is TELA in?
TELA Bio Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did TELA Bio Inc. go public?
TELA Bio Inc. (TELA) completed its IPO in 2019.What are analysts saying about TELA?
TELA Bio Inc. has had 3 recent analyst actions on file. The most recent action was from Craig Hallum: Buy with a $200.00 price target on 2026-09-25.What companies are similar to TELA?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare TELA side-by-side with any of them on Quantisnow.How can I track TELA on Quantisnow?
Quantisnow aggregates TELA Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TELA to receive live email and push alerts on every new disclosure.